1-16 of 16
Allan J. Pantuck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Debashis Sarker, Nancy A. Dawson, Ana M. Aparicio, Tanya B. Dorff, Allan J. Pantuck, Ulka N. Vaishampayan, Lynn Henson, Lakshmi Vasist, Sumita Roy-Ghanta, Michele Gorczyca, Whitney York, Gopinath Ganji, Jerry Tolson, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5248–5257.
https://doi.org/10.1158/1078-0432.CCR-21-1115
Published: 01 October 2021
View article titled, A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Rahul R. Aggarwal, Michael T. Schweizer, David M. Nanus, Allan J. Pantuck, Elisabeth I. Heath, Eric Campeau, Sarah Attwell, Karen Norek, Margo Snyder, Lisa Bauman, Sanjay Lakhotia, Felix Y. Feng, Eric J. Small, Wassim Abida, Joshi J. Alumkal
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5338–5347.
https://doi.org/10.1158/1078-0432.CCR-20-1707
Published: 15 October 2020
View article titled, A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Open the PDF for A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial

Anup Patel, Alain Ravaud, Robert J. Motzer, Allan J. Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, Daniel J. George
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4863–4868.
https://doi.org/10.1158/1078-0432.CCR-20-0704
Published: 15 September 2020
View article titled, Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial
Open the PDF for Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial in another window
Journal Articles

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Daniel J. George, Jean-Francois Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Frede Donskov, Bernard Escudier, Sherry Li, Michelle Casey, Olga Valota, Brigitte Laguerre, Allan J. Pantuck, Hardev S. Pandha, Anup Patel, Maria Lechuga, Alain Ravaud
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1165–1173.
https://doi.org/10.1158/1078-0432.CCR-18-1724
Published: 15 February 2019
View article titled, Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Open the PDF for Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis in another window
Includes: Supplementary data
Journal Articles

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study

Daniel J. George, Jean-François Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Bernard Escudier, Paola Gerletti, Sherry Li, Michelle Casey, Brigitte Laguerre, Hardev S. Pandha, Allan J. Pantuck, Anup Patel, Maria J. Lechuga, Alain Ravaud
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1554–1561.
https://doi.org/10.1158/1078-0432.CCR-17-2822
Published: 02 April 2018
View article titled, Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study
Open the PDF for Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study in another window
Journal Articles

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

David F. McDermott, Su-Chun Cheng, Sabina Signoretti, Kim A. Margolin, Joseph I. Clark, Jeffrey A. Sosman, Janice P. Dutcher, Theodore F. Logan, Brendan D. Curti, Marc S. Ernstoff, Leonard Appleman, Michael K.K. Wong, Nikhil I. Khushalani, Leslie Oleksowicz, Ulka N. Vaishampayan, James W. Mier, David J. Panka, Rupal S. Bhatt, Alexandra S. Bailey, Bradley C. Leibovich, Eugene D. Kwon, Fairooz F. Kabbinavar, Arie S. Belldegrun, Robert A. Figlin, Allan J. Pantuck, Meredith M. Regan, Michael B. Atkins
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (3): 561–568.
https://doi.org/10.1158/1078-0432.CCR-14-1520
Published: 01 February 2015
View article titled, The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
Open the PDF for The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma in another window
Journal Articles

Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma

Tobias Klatte, Allan J. Pantuck, Jonathan W. Said, David B. Seligson, Nagesh P. Rao, Jeffrey C. LaRochelle, Brian Shuch, Amnon Zisman, Fairooz F. Kabbinavar, Arie S. Belldegrun
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1162–1169.
https://doi.org/10.1158/1078-0432.CCR-08-1229
Published: 19 February 2009
View article titled, Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma
Open the PDF for Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma in another window
Journal Articles

Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma

Tobias Klatte, David B. Seligson, Stephen B. Riggs, John T. Leppert, Maria K. Berkman, Mark D. Kleid, Hong Yu, Fairooz F. Kabbinavar, Allan J. Pantuck, Arie S. Belldegrun
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (24): 7388–7393.
https://doi.org/10.1158/1078-0432.CCR-07-0411
Published: 19 December 2007
View article titled, Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma
Open the PDF for Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma in another window
Journal Articles

Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials

John S. Lam, Allan J. Pantuck, Arie S. Belldegrun, Robert A. Figlin
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 703s–708s.
https://doi.org/10.1158/1078-0432.CCR-06-1864
Published: 25 January 2007
View article titled, Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials
Open the PDF for Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials in another window
Journal Articles

Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference

Michael B. Atkins, Marc S. Ernstoff, Robert A. Figlin, Keith T. Flaherty, Daniel J. George, William G. Kaelin, Jr., Eugene D. Kwon, Towia A. Libermann, W. Marston Linehan, David F. McDermott, Augusto C. Ochoa, Allan J. Pantuck, Brian I. Rini, Mark A. Rosen, Jeffrey A. Sosman, Vikas P. Sukhatme, Johannes W. Vieweg, Christopher G. Wood, Laura King
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 667s–670s.
https://doi.org/10.1158/1078-0432.CCR-06-2231
Published: 25 January 2007
View article titled, Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
Open the PDF for Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference in another window
Journal Articles

Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy?

Allan J. Pantuck, Arie S. Belldegrun, Robert A. Figlin
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 693s–696s.
https://doi.org/10.1158/1078-0432.CCR-06-1916
Published: 25 January 2007
View article titled, Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy?
Open the PDF for Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy? in another window
Journal Articles

Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer

Allan J. Pantuck, John T. Leppert, Nazy Zomorodian, William Aronson, Jenny Hong, R. James Barnard, Navindra Seeram, Harley Liker, Hejing Wang, Robert Elashoff, David Heber, Michael Aviram, Louis Ignarro, Arie Belldegrun
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 4018–4026.
https://doi.org/10.1158/1078-0432.CCR-05-2290
Published: 03 July 2006
View article titled, Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer
Open the PDF for Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer in another window
Journal Articles

Gene Signatures of Progression and Metastasis in Renal Cell Cancer

Jon Jones, Hasan Otu, Dimitrios Spentzos, Shakirahmed Kolia, Mehmet Inan, Wolf D. Beecken, Christian Fellbaum, Xuesong Gu, Marie Joseph, Allan J. Pantuck, Dietger Jonas, Towia A. Libermann
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 5730–5739.
https://doi.org/10.1158/1078-0432.CCR-04-2225
Published: 22 August 2005
View article titled, Gene Signatures of Progression and Metastasis in Renal Cell Cancer
Open the PDF for Gene Signatures of Progression and Metastasis in Renal Cell Cancer in another window
Journal Articles

Epithelial Cell Adhesion Molecule (KSA) Expression: Pathobiology and Its Role as an Independent Predictor of Survival in Renal Cell Carcinoma

David B. Seligson, Allan J. Pantuck, Xueli Liu, Yunda Huang, Steven Horvath, Matthew H. T. Bui, Ken-ryu Han, Adrian J. L. Correa, Mervi Eeva, Sheila Tze, Arie S. Belldegrun, Robert A. Figlin
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (8): 2659–2669.
https://doi.org/10.1158/1078-0432.CCR-1132-03
Published: 20 April 2004
View article titled, Epithelial Cell Adhesion Molecule (KSA) Expression: <subtitle>Pathobiology and Its Role as an Independent Predictor of Survival in Renal Cell Carcinoma</subtitle>
Open the PDF for Epithelial Cell Adhesion Molecule (KSA) Expression: <subtitle>Pathobiology and Its Role as an Independent Predictor of Survival in Renal Cell Carcinoma</subtitle> in another window
Journal Articles

Pathobiology, Prognosis, and Targeted Therapy for Renal Cell Carcinoma: Exploiting the Hypoxia-Induced Pathway

Allan J. Pantuck, Gang Zeng, Arie S. Belldegrun, Robert A. Figlin
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (13): 4641–4652.
Published: 27 October 2003
View article titled, Pathobiology, Prognosis, and Targeted Therapy for Renal Cell Carcinoma: <subtitle>Exploiting the Hypoxia-Induced Pathway</subtitle>
Open the PDF for Pathobiology, Prognosis, and Targeted Therapy for Renal Cell Carcinoma: <subtitle>Exploiting the Hypoxia-Induced Pathway</subtitle> in another window
Journal Articles

Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: Implications for Prognosis and Therapy

Matthew H. T. Bui, David Seligson, Ken-ryu Han, Allan J. Pantuck, Frederick J. Dorey, Yunda Huang, Steve Horvath, Bradley C. Leibovich, Shefali Chopra, Shu-Yuan Liao, Eric Stanbridge, Michael I. Lerman, Aarno Palotie, Robert A. Figlin, Arie S. Belldegrun
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (2): 802–811.
Published: 01 February 2003
View article titled, Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: <subtitle>Implications for Prognosis and Therapy</subtitle>
Open the PDF for Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: <subtitle>Implications for Prognosis and Therapy</subtitle> in another window